A Comparative Study of Diosmin-Hesperidin and Loratadine for Preventing G-CSF Induced Bone Pain in Patients With Hematological Malignancies

What this Trial Is About

Researchers are evaluating the best way to prevent bone pain caused by Granulocyte Colony-Stimulating Factor (G-CSF) in adults with blood cancers such as leukemia or lymphoma. This study compares the effectiveness of two oral medications, diosmin-hesperidin (a flavonoid supplement) and loratadine (an anti-allergy drug), alone and in combination, to reduce this common and painful side effect. The trial seeks to find whether these treatments can better manage G-CSF-induced bone pain and improve patient comfort. Participants will be randomly assigned to one of four groups: a control group receiving no specific pain prevention, a loratadine group taking 10 mg once daily, a diosmin-hesperidin group taking 500 mg twice daily, or a combination group taking both medications. All treatments start 30 minutes before filgrastim administration and continue for five days. Filgrastim is given as part of standard care for the underlying blood condition. This open-label trial is conducted at Alexandria University Hospitals. Before treatment, participants will provide medical history and undergo blood tests and pain assessments. Pain severity and interference will be measured with the Brief Pain Inventory at baseline, 24 hours after the first filgrastim dose, and after five days of treatment. Researchers will also monitor tumor necrosis factor-alpha levels in the blood as a marker of inflammation. The study includes safety evaluations and will analyze data to identify factors influencing bone pain. Participation lasts through the treatment and assessment period, with results guiding future pain management strategies.

Comparing Diosmin-Hesperidin and Loratadine to Prevent Bone Pain From G-CSF in Patients With Blood Cancers